NCT01538381View on ClinicalTrials.gov

Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
DRUG

Afatinib

Afatinib for 2 weeks at a dose of 40 mg/day

OTHER

Observation

Observation

Trial Locations (4)

1000

Institut Jules Bordet, Brussels

1200

Cliniques Universitaires St. Luc, Brussels

3000

U.Z. Leuven - Campus Gasthuisberg, Leuven

20133

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori, Milan

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT01538381 - Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter